Medical Marijuana Program Connection

OCTOBER 6, 2023

AUSTIN, Texas–(BUSINESS WIRE)–Anebulo Pharmaceuticals, Inc. Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) (“Anebulo”), today announced. Read More

Pharmaceutical 64

Pharmaceutical Cannabinoids Business 64

Veriheal

APRIL 11, 2022

The final goal is to introduce medicinal cannabis products to the pharmaceutical drug market. This means that the medical and scientific communities can now celebrate broader access to research for the production of pharmaceutical products that are safer than smokable or vaporizable cannabis. Drug Enforcement Agency (DEA).

Cannabis 96

Cannabis Pharmaceutical Cannabinoids DEA 96

Cannabis Law Report

JANUARY 17, 2023

Celadon Pharmaceuticals PLC shares rose on Monday after the company said that its Midlands facility has been registered for the good manufacturing practice standard by the U.K.’s The UK-based pharmaceutical company focused on […]. ’s health watchdog for the production of its medicinal cannabis. pence, or 11%, at 57.0

Pharmaceutical 52

Pharmaceutical Cannabis Medicine 52

Cannabis Law Report

MAY 26, 2023

Multinational operator to supply pharmaceutical-grade CBD extract for European patients TOCANCIPÁ, Colombia, May 25, 2023 (GLOBE NEWSWIRE) — Clever Leaves Holdings Inc.

Pharmaceutical 52

Pharmaceutical CBD Extraction Cannabis 52

The Fresh Toast

MARCH 20, 2019

Consumers Are Replacing Pharmaceuticals With Medical Marijuana In recent years, certain states that have medical and/or recreational cannabis programs in place have experienced decreases in the number of opioid overdoses. The post Consumers Are Replacing Pharmaceuticals With Medical Marijuana appeared first on The Fresh Toast.

Marijuana 106

Marijuana Pharmaceutical Cannabis Recreational 106

Project CBD

OCTOBER 26, 2023

United Kingdom-based GW Pharmaceuticals has produced the world’s first approved cannabis-based medicines for the UK, US, and European markets, Sativex® and Epidiolex®. GW Pharmaceuticals’ research on glioblastoma multiforme (GBM) is important and promising. Note: In May 2021, GW Pharmaceuticals was acquired by Jazz Pharmaceuticals.]

Cannabis 337

Cannabis Cannabinoids THC CBD 337

Cannabis Law Report

AUGUST 10, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, today reported that its subsidiary Oravax Medical Inc. About MyMD Pharmaceuticals, Inc.

Clinical Trials 105

Clinical Trials Pharmaceutical CBD Research and Development 105

Cannabis Law Report

MARCH 18, 2021

Clever Leaves Partners with Leading European Pharmaceutical Company to Market EU-GMP Certified Medical Cannabis Products NEW YORK, March 17, 2021… Read More.

Pharmaceutical 98

Pharmaceutical Cannabis 98

Cannabis Law Report

MAY 12, 2021

BALTIMORE–(BUSINESS WIRE)–MyMD Pharmaceuticals, Inc. Nasdaq: MYMD), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing… Read More.

Pharmaceutical 75

Pharmaceutical Business 75

United Patients Group

MARCH 15, 2023

The post Can Cannabis Help Patients Titrate Off Other Pharmaceutical Drugs? Remember to consult or discuss this with your doctor or medical professional before starting to titrate off your medications. appeared first on United Patients Group.

Cannabis 98

Cannabis Patients Pharmaceutical Chronic Pain 98

Cannabis Law Report

JANUARY 23, 2023

VF1883 Pharmaceuticals, a medical cannabis producer based in Benavente, has been declared insolvent by the Santarém Court. The insolvency declaration judgment, requested by one of the company’s more than 80 creditors, was handed down on 23 November 2022 and has now become final, in January 2023.

Cannabis 52

Cannabis Pharmaceutical Access Compliance 52

Cannabis Law Report

MAY 12, 2020

GW Pharmaceuticals lost $8 million in its latest quarter – an improvement over the previous three-month period – but the United Kingdom-based medical cannabinoid company … Read More.

Pharmaceutical 98

Pharmaceutical Cannabinoids 98

Cannabis Law Report

OCTOBER 25, 2022

The transformative deal is expected to connect Flora Growth’s Colombian-grown cannabis directly with German-based pharmaceutical and medical cannabis distribution. The company signed a definitive agreement with Franchise Global Health, which has principal operations in Europe’s largest economy.

Cannabis 59

Cannabis Pharmaceutical 59

Cannabis Law Report

JUNE 17, 2021

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) raised its full-year 2021 financial guidance based on the acquisition of GW Pharmaceuticals, which was bought on May 5, 2021. regulatory approval, and our new cannabinoid research platform,” said Renée Galá, the chief financial officer of Jazz Pharmaceuticals.

Pharmaceutical 108

Pharmaceutical Clinical Trials Cannabinoids Patients 108

Cannabis Law Report

FEBRUARY 3, 2021

The post Jazz Pharmaceuticals Pick Up GW Pharma For A Cool $7.2 For those of you living under a rock here is the news. We thought we better report it along with… Read More. billion first appeared on Cannabis Law Report.

Pharmaceutical 98

Pharmaceutical Cannabis Law 98

Cannabis Law Report

JUNE 7, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. About MyMD Pharmaceuticals, Inc. MyMD is a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms.

Pharmaceutical 79

Pharmaceutical CBD Clinical Trials Conditions 79

Cannabis Law Report

DECEMBER 23, 2021

DUBLIN–(BUSINESS WIRE)– “The Pharmaceutical Cannabis Report: 2nd Edition” report has been added to ResearchAndMarkets.com’s offering. In both Europe and the United States, the sales of unapproved cannabis products such as smokable flower and full spectrum oils dwarf those of approved pharmaceuticals.

Pharmaceutical 96

Pharmaceutical Cannabis Cannabinoids Clinical Trials 96

Cannabis Law Report

MAY 31, 2023

MGC Pharmaceuticals Ltd (LSE:MXC, OTC:MGCLF, ASX:MXC) has passed a significant milestone, delivering the first doses of its CannEpil® units to patients in the United Kingdom, paving the way for the treatment of refractory epilepsy, an unmet need in the country.

Epilepsy 52

Epilepsy Pharmaceutical Treatment Patients 52

Cannabis Law Report

MARCH 20, 2021

Algernon Pharmaceuticals Inc. CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (“Algernon”), a clinical stage pharmaceutical development company, is pleased to announce… Read More.

Pharmaceutical 98

Pharmaceutical Programs Cannabis 98

Medical Marijuana Program Connection

MAY 12, 2023

–(BUSINESS WIRE)– #pharma–Summary: Virpax Pharmaceuticals to Present at Upcoming CB Tech Watch Seminar Source link. BERWYN, Pa.–(BUSINESS Read More

Pharmaceutical 40

Pharmaceutical Business 40

Cannabis Law Report

MARCH 26, 2022

Jazz Pharmaceuticals is investing £75m in a plant based at Kent Science Park (KSP) in Sittingbourne, Kent. ” ‘Strategic investment’ Jazz Pharmaceuticals currently manufactures the extract, active pharmaceutical ingredients and the formulated drug products at KSP, occupying 12 buildings with more than 400 employees.

Pharmaceutical 52

Pharmaceutical Cannabis Medicine Cannabinoids 52

Medical Marijuana Program Connection

MARCH 2, 2023

MyMD Pharmaceuticals, Inc. MYMD announced that the U.S. Drug Enforcement Administration has conducted a scientific review and determined that investigational. Read More

Pharmaceutical 52

Pharmaceutical DEA CBD 52

Cannabis Law Report

FEBRUARY 23, 2022

(TSX: LABS) (OTCQX: MEDIF ) (FSE: MLZ) (“MediPharm” or the “Company”) a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it has completed a US FDA DMF for pure natural CBD API. The DMF will enable MediPharm to supply approved API to pharmaceutical companies currently conducting late-stage research.

Pharmaceutical 52

Pharmaceutical Cannabinoids Cannabis CBD 52

Cannabis Law Report

SEPTEMBER 2, 2022

The pharmaceutical industry takes a serious economic hit after states legalize marijuana—with an average market loss of nearly $10 billion for drugmakers per each legalization event—according to a first-of-its-kind study. By expanding access and, thus use, legalization could permit cannabis to compete with conventional pharmaceuticals.

Marijuana 52

Marijuana Pharmaceutical Legalization Cannabis 52

Cannabis Law Report

FEBRUARY 3, 2021

The post February 4 2021: Jim Cramer on Jazz Pharmaceuticals buying GW Pharma for $7.2 … Read More. billion first appeared on Cannabis Law Report.

Pharmaceutical 98

Pharmaceutical Cannabis Law 98

Cannabis Law Report

JANUARY 6, 2022

AUSTIN, Texas–(BUSINESS WIRE)– Anebulo Pharmaceuticals, Inc. About Anebulo Pharmaceuticals, Inc. Anebulo Pharmaceuticals, Inc. Anebulo Pharmaceuticals, Inc. Wainwright BioConnect Virtual Conference being held January 10-13, 2022. Eastern time on the Investors section of Anebulo’s website. Scott Anderson.

Pharmaceutical 52

Pharmaceutical Cannabinoids Clinical Trials Business 52

Medical Marijuana Program Connection

JANUARY 31, 2023

–(BUSINESS WIRE)–Virpax® Pharmaceuticals, Inc. BERWYN, Pa.–(BUSINESS Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain. Read More

Pharmaceutical 52

Pharmaceutical Business 52

Cannabis Law Report

OCTOBER 20, 2020

Here’s a quick blurb……… The rapid growth of cannabis-based medicines is becoming a significant disruptor of the global pharmaceutical industry, but the point of … Read More. The post Prohibition Partners (UK) Publish "The Pharmaceutical Cannabis Report" first appeared on Cannabis Law Report.

Pharmaceutical 59

Pharmaceutical Cannabis Medicine Law 59

Medical Marijuana Program Connection

APRIL 20, 2023

Fiji Council of Churches endorses the legalization of marijuana but only for pharmaceutical or medicinal purposes The Fiji Council of. Read More

Marijuana 52

Marijuana Pharmaceutical Medicine Legalization 52

Cannabis Law Report

DECEMBER 15, 2021

Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (NASDAQ: CGC ) has entered into an agreement to divest its subsidiary business, C³ Cannabinoid Compound Company GmbH (“C3”), to Dermapharm Holding SE (“Dermapharm”) (WKN: A2GS5D, ISIN: DE000A2GS5D8), a European pharmaceutical company headquartered in Grünwald, Germany.

Cannabinoids 52

Cannabinoids Pharmaceutical Cannabis CBD 52

Medical Marijuana Program Connection

JANUARY 18, 2023

–(BUSINESS WIRE)–Virpax® Pharmaceuticals, Inc. BERWYN, Pa.–(BUSINESS Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain. Read More.

Pharmaceutical 52

Pharmaceutical Business 52

Cannabis Law Report

MAY 6, 2021

AUSTIN, Texas–(BUSINESS WIRE)–Anebulo Pharmaceuticals, Inc. Nasdaq: ANEB) (“Anebulo” or the “Company”), a clinical-stage biotechnology company developing novel solutions for people… Read More.

Pharmaceutical 59

Pharmaceutical Business 59

Cannabis Law Report

FEBRUARY 3, 2021

The post February 4 2021: Jazz Pharmaceuticals buys GW Pharma for $7.2 … Read More. billion first appeared on Cannabis Law Report.

Pharmaceutical 85

Pharmaceutical Cannabis Law 85

Cannabis Law Report

APRIL 13, 2021

Beckley Psytech, a private company dedicated to addressing neurological and psychiatric disorders through psychedelic medicine, has appointed ex-GW Pharmaceuticals CFO… Read More.

Pharmaceutical 59

Pharmaceutical Medicine Cannabis 59

Project CBD

NOVEMBER 11, 2023

In general, I think that botanical medicine is safer than pharmaceutical medicine, that the chances of causing harm are much less. I include pharmaceutical drugs in that category. In general, I think that botanical medicine is safer than pharmaceutical medicine. They’re less interested in the pharmaceutical versions.

Medicine 294

Medicine Cannabis THC CBD 294

Cannabis Law Report

JULY 7, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. About MyMD Pharmaceuticals, Inc. MyMD is a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms. Eurofins is a global leader in food, environment, and pharmaceutical product testing.

Pharmaceutical 105

Pharmaceutical CBD Data Clinical Trials 105

Cannabis Law Report

AUGUST 10, 2021

We are delighted by today’s decision from the MHRA for this new indication, which represents a significant step forward for TSC patients in the UK, many of whom may benefit from this new treatment,” said Chris Tovey , Executive Vice President, Chief Operating Officer and Managing Director, Europe & International at Jazz Pharmaceuticals.

Pharmaceutical 98

Pharmaceutical Epilepsy Treatment Medicine 98